New Digital Advocacy “Take Action” Center helps members stay informed about CLSA’s advocacy efforts, view priority legislation, contact their elected officials and more.
CLSA is pleased to provide you with this exclusive 2016 federal, state and local election update, and what these results mean for California’s life sciences sector.
California Life Sciences Association Partners with LA BioMed and Lab Launch to Grow World-Class Life Sciences Innovation Hub in Los Angeles; Opens Los Angeles Office
CLSA & OCTANe today announced a formal alliance to strategically accelerate the growth of Orange County’s life sciences sector.
GEN News tabulates a 2016 list of the top 10 U.S. biopharma clusters in the nation, relying on portions data from CLSA’s 2016 California Life Sciences Industry Report.
Check out this California Life Science Association (CLSA) and Boston Consulting Group report that details trending data about the FDA’s drug review performance. The infographic report shows that the FDA has accelerated review times, descending from an average of 21 months in 2009 to 10 months in 2015, and highlights key areas for improvement moving forward.
Featured in the San Diego Business Journal, Sara Radcliffe, president and CEO of the California Life Sciences Association, discusses some of the issues and obstacles facing the life sciences.
California Life Sciences Association (CLSA) and Boston Consulting Group (BCG) report finds progress made in FDA medical device review times, but room for improvement remains
CLSA Pres. & CEO Sara Radcliffe recently sat down with mendelspod.com to discuss the value of medical innovation in California.
CLSA President & CEO Sara Radcliffe makes the case in this San Jose Mercury News op-ed on how California should value innovation in life sciences.